hemato-oncology

Patient Insights from AplusA’s Multiple Myeloma Tracker

October 30, 2019 | AplusA

A thoughtfully developed tracker can provide deep insights on any therapeutic area. Using the results of a syndicated AplusA tracking study on the multiple myeloma market, this series of blog...

Read More

hemato-oncology

Multiple Myeloma Market Dynamics Revealed by AplusA Tracker

October 30, 2019 | AplusA

A thoughtfully developed tracker can provide deep insights on any therapeutic area. Using the results of a syndicated AplusA tracking study on the multiple myeloma market, this series of blog...

Read More

hemato-oncology

Brand Performance Insights from AplusA's Multiple Myeloma Tracker

October 28, 2019 | AplusA

A thoughtfully developed tracker can provide deep insights on any therapeutic area. Using the results of a syndicated AplusA tracking study on the multiple myeloma market, this series of blog...

Read More

hemato-oncology

Key Insights from a Multiple Myeloma Tracker

October 21, 2019 | AplusA

A thoughtfully developed tracker can provide deep insights on any therapeutic area. Using the results of a syndicated AplusA tracking study on the Multiple Myeloma market, this series of blog...

Read More

Healthcare Industry hemato-oncology

Who Are The Key Hemato-Oncology Market Stakeholders?

April 9, 2019 | AplusA

As a marketing professional in the healthcare industry, you need to accurately identify the criteria that define your specific target population in order to size your market and build your...

Read More

Healthcare Industry Digital hemato-oncology

Who are the Digital Opinion Leaders in Hemato-Oncology?

April 4, 2019 | AplusA

KOLs (Key Opinion Leaders) have long since played an important and influential role in the healthcare industry. In recent years we have seen the emergence and rapid rise in the influence of DOLs...

Read More

Healthcare Industry Market Research Industry hemato-oncology

5 Benefits of Syndicated Research in the Hematology Oncology Market

April 1, 2019 | AplusA

In the rapidly evolving onco -hematology market, syndicated research provides critical insights based on real-world data in order to support strategic decision making within pharmaceutical and ...

Read More

hemato-oncology

DLBCL Treatment: A Quick Overview

March 11, 2019 | AplusA

DLBCL is the most common form of non-Hodgkin’s lymphoma (NHL), constituting 30% to 58% of lymphoma cases.

Read More

hemato-oncology

Why is the Hemato-Oncology Market Complex for Market Researchers?

February 27, 2019 | AplusA

The hematology oncology market is one of the most rapidly developing, with over sixty oncology drugs having been approved by the FDA in the last five years. Advances in targeted therapies,...

Read More

hemato-oncology

Chronic Lymphocytic Leukemia: Current and Future CLL Treatments

January 24, 2019 | AplusA

Chronic Lymphocytic Leukemia is the most common form of leukemia in Western countries. Although currently incurable, there have been significant advances in research efforts of CLL treatments in...

Read More